Tyme Technologies, Inc. (OTCMKTS:TYMI) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On July30, 2018, Tyme released financial information for the first quarter ended June30, 2018. The related press release is attached as Exhibit 99.1.
|Item 2.02||Financial Statements and Exhibits.|
Set forth below is a list of the exhibits to this Current Report on Form 8-K.
|Press release, dated July30, 2018|
TYME TECHNOLOGIES, INC. ExhibitEX-99.1 2 d586428dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tyme Technologies Provides Clinical and Corporate Update for Fiscal 1Q 2019 July 30,…To view the full exhibit click
About Tyme Technologies, Inc. (OTCMKTS:TYMI)
Tyme Technologies, Inc., formerly Global Group Enterprises Corp., conducts majority of its research and development activities and other business operations, through its subsidiary, Tyme Inc. (Tyme). Tyme is a clinical-stage biopharmaceutical company. Tyme is focused on the development and commercialization of highly targeted cancer therapeutics with a range of oncology indications. The Company’s another subsidiary, Luminant Biosciences, LLC, conducts the initial research and development of the Company’s therapeutic platform. The Company is formulating its regulatory and drug development program for its lead drug candidate, SM-88, and working towards the initiation of its Phase II clinical trial. The Company is also evaluating the expansion of its Phase II program to other types of cancer. The Company has not generated any revenue.